 |
인쇄하기
취소
|
Sanofi-Aventis Korea to launch rapid-acting insulin glulisine
Sanofi-Aventis Korea said it will market Apidra (insulin glulisine) for the treatment of type 1 and type 2 diabetes from next month.
The company said it has added another diabetes drug to its catalog with the approval of insulin glulisine [rDNA origin] injection, a rapid acting insulin analogue for treatment of adult patients with diabetes mellitus for the control of hyperglycemia.
Compar...
The company said it has added another diabetes drug to its catalog with the approval of insulin glulisine [rDNA origin] injection, a rapid acting insulin analogue for treatment of adult patients with diabetes mellitus for the control of hyperglycemia.
Compar...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.